[Pulmonary mycobacteriosis due to Mycobacterium xenopi" in-vitro sensitivity to classical antitubercular agents and clinical development].
Out of 11 patients suffering from Mycobacterium xenopi lung disease, 9 were treated with an empiric antituberculous triple chemotherapy until specific identification and antibiogram were available. Despite the important "in vitro" resistance to drugs, most of the patients improved; in the other patients, the impairment was always due to the underlying pathology. We conclude that the "in vivo" response of M. xenopi infections to antituberculous drugs is little influenced by the "in vitro" sensitivity.
Baugnée
P E
PE
Service de Pneumologie, Cliniques Universitaires UCL de Mont-Godinne, Yvoir.
Pouthier
F
F
Delaunois
L
L
D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy / Q000382:microbiology*; D009170:Nontuberculous Mycobacteria / Q000187:drug effects / Q000302:isolation & purification*; D018410:Pneumonia, Bacterial / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000382:microbiology*; D011859:Radiography
D000995:Antitubercular Agents
Mycobactériose pulmonaire à Mycobacterium xenopi: sensibilité "in vitro" aux antituberculeux classiques et evolution clinique.